[{"address1": "3963 Maple Avenue", "address2": "Suite 350", "city": "Dallas", "state": "TX", "zip": "75219", "country": "United States", "phone": "972 499 3350", "website": "https://instilbio.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Instil Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing a pipeline of novel therapies. The company develops cell therapy of tumor infiltrating lymphocyte (TIL) for the treatment of cancer. It is developing early-stage pipeline of CoStAR-TIL and other novel TIL technologies. Instil Bio, Inc. was incorporated in 2018 and is headquartered in Dallas, Texas.", "fullTimeEmployees": 49, "companyOfficers": [{"maxAge": 1, "name": "Mr. Bronson  Crouch", "age": 50, "title": "Chairman & CEO", "yearBorn": 1973, "fiscalYear": 2023, "totalPay": 1140189, "exercisedValue": 0, "unexercisedValue": 35349}, {"maxAge": 1, "name": "Dr. Sandeep  Laumas M.D.", "age": 54, "title": "CFO & Chief Business Officer", "yearBorn": 1969, "fiscalYear": 2023, "totalPay": 741521, "exercisedValue": 0, "unexercisedValue": 61910}, {"maxAge": 1, "name": "Dr. Mark E. Dudley Ph.D.", "title": "Chief Scientific Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 7, "boardRisk": 8, "compensationRisk": 9, "shareHolderRightsRisk": 8, "overallRisk": 8, "governanceEpochDate": 1730419200, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 2, "previousClose": 22.0, "open": 21.3, "dayLow": 19.28, "dayHigh": 21.3, "regularMarketPreviousClose": 22.0, "regularMarketOpen": 21.3, "regularMarketDayLow": 19.28, "regularMarketDayHigh": 21.3, "beta": 1.738, "forwardPE": -1.2732521, "volume": 96714, "regularMarketVolume": 96714, "averageVolume": 128100, "averageVolume10days": 128060, "averageDailyVolume10Day": 128060, "bid": 19.25, "ask": 20.09, "bidSize": 100, "askSize": 100, "marketCap": 129538920, "fiftyTwoWeekLow": 7.35, "fiftyTwoWeekHigh": 92.0, "fiftyDayAverage": 25.325, "twoHundredDayAverage": 21.4987, "currency": "USD", "enterpriseValue": 128317200, "floatShares": 2368595, "sharesOutstanding": 6525890, "sharesShort": 375997, "sharesShortPriorMonth": 190104, "sharesShortPreviousMonthDate": 1727654400, "dateShortInterest": 1730332800, "sharesPercentSharesOut": 0.057800002, "heldPercentInsiders": 0.12863, "heldPercentInstitutions": 0.80705, "shortRatio": 2.29, "shortPercentOfFloat": 0.1003, "impliedSharesOutstanding": 6525890, "bookValue": 34.722, "priceToBook": 0.57168365, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1719705600, "netIncomeToCommon": -119576000, "trailingEps": -11.56, "forwardEps": -12.07, "lastSplitFactor": "1:20", "lastSplitDate": 1701993600, "enterpriseToEbitda": -1.944, "52WeekChange": 1.6680107, "SandP52WeekChange": 0.22263205, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "TIL", "underlyingSymbol": "TIL", "shortName": "Instil Bio, Inc.", "longName": "Instil Bio, Inc.", "firstTradeDateEpochUtc": 1616160600, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EST", "uuid": "f6e98ce3-ca96-34e6-a1c6-796bed2d60df", "messageBoardId": "finmb_638929728", "gmtOffSetMilliseconds": -18000000, "currentPrice": 19.85, "targetHighPrice": 180.0, "targetLowPrice": 52.0, "targetMeanPrice": 114.0, "targetMedianPrice": 110.0, "recommendationMean": 1.75, "recommendationKey": "buy", "numberOfAnalystOpinions": 3, "totalCash": 148772992, "totalCashPerShare": 22.874, "ebitda": -66022000, "totalDebt": 85615000, "quickRatio": 14.459, "currentRatio": 15.057, "debtToEquity": 43.901, "returnOnAssets": -0.1245, "returnOnEquity": -0.48654, "freeCashflow": -27199750, "operatingCashflow": -52811000, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2025-01-11"}]